We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
ARTICLE · 27 AUGUST 2015
Amgen And Apotex Do The Biosimilar Patent Dance
Foley & Lardner LLP
Amgen has filed a complaint under the Biologics Price Competition and Innovation Act (BPCIA), asserting that a biosimilar application filed by Apotex, Inc. infringes two of its patents.
United StatesIntellectual Property






